Stockscreener 앱 받기
31.52
5.19%
1.555
시간 외 거래:
31.49
-0.035
-0.11%
전일 마감가:
$29.97
열려 있는:
$29.92
하루 거래량:
143.51K
Relative Volume:
0.80
시가총액:
$1.47B
수익:
-
순이익/손실:
-
주가수익비율:
-38.75
EPS:
-0.8135
순현금흐름:
-
1주 성능:
-14.17%
1개월 성능:
+24.60%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$29.54
$32.19
1주일 범위
$29.54
$37.09
52주 변동 폭
$23.00
$38.87
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
명칭
Hemab Therapeutics Holdings Inc
전화
45 2138 7627
주소
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
31.52 | 1.40B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc 주식(COAG)의 최신 뉴스
Price to book forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Enterprise value to revenue forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to earnings forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Enterprise value to EBITDA forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to sales forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Hemab Therapeutics Hldgs Price Target Maintained With a $40.00/Share by HC Wainwright & Co. - Moomoo
Hemab Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:COAG) - TradingView
COAG Forecast — Price Target — Prediction for 2027 - TradingView
COAG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress - The Manila Times
Hemab brings nine bleeding-disorder studies to ISTH 2026 in Paris - Stock Titan
Enterprise value to EBIT forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics Holdings, Inc.(NasdaqGS: COAG) added to S&P TMI Index - marketscreener.com
This GE Vernova analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
COAG Initiated Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Hemab Therapeutics (COAG) stake rises as RA Capital buys 67,669 shares - Stock Titan
Hemab Therapeutics Holdings Ord Shs (Proposed) - TradingKey
Hemab soars 89% on debut as biopharma IPOs stay strong in May - BioWorld News
Hemab Therapeutics Holdings, Inc.Common Stock (COAG) Stock Price, News, Quote & History - FinancialContent
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans - Yahoo Finance
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COAG: Lead asset moves to phase III, with robust pipeline and funding secured through 2029 - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics Pulls Back After 53% IPO Surge - Bez Kabli
Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO - Novo Holdings
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis & ETF Price Forecast - Intellectia AI
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Latest COAG ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Hemab Therapeutics Hldgs Initiated at Outperform by Evercore ISI Group - Moomoo
COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus
COAG Initiates Coverage by Goldman Sachs -- Price Target Announced at $36 - GuruFocus
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42 - Moomoo
Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo
Hemab Therapeutics Hldgs Price Target Announced at $50.00/Share by Evercore ISI Group - Moomoo
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39 - Moomoo
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
Hemab Therapeutics Holdings Inc (COAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Hemab Therapeutics Holdings Inc 주식 (COAG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Jun 15 '26 |
Buy |
24.89 |
6,146 |
152,974 |
6,383,114 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 19 '26 |
Buy |
24.97 |
3,802 |
94,936 |
6,375,972 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 20 '26 |
Buy |
24.94 |
996 |
24,840 |
6,376,968 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 12 '26 |
Buy |
24.90 |
6,387 |
159,036 |
6,372,170 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 11 '26 |
Buy |
24.81 |
39,869 |
989,226 |
6,365,783 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 07 '26 |
Buy |
24.46 |
9,906 |
242,323 |
6,324,431 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 08 '26 |
Buy |
24.98 |
1,483 |
37,045 |
6,325,914 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 04 '26 |
Buy |
18.00 |
2,675,000 |
48,150,000 |
6,149,096 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 05 '26 |
Buy |
24.63 |
97,411 |
2,399,546 |
6,246,507 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 06 '26 |
Buy |
24.60 |
68,018 |
1,673,399 |
6,314,525 |
1.18%
2.48%
자본화:
|
볼륨(24시간):